Micro Aftermath Archived

Haemonetics Corporation (HAE) aguarda validação do mercado

Atividade em declínio — narrativa perdendo relevância.

Pontuação 0,3

Velocidade ▲ 0,0

Artigos 5

Fontes 2

Principais Movimentações

Ticker	Setor	Variação
HAE	Health Care	+20,9%

Linha do Tempo de Sentimento

Desempenho por Setor

Linha do Tempo de Eventos

Ago 09, 2026 Haemonetics Q1 Earnings Call Highlights Bullish

Ago 07, 2026 Haemonetics Corp Q1 Sales Increase Neutral

Mai 21, 2026 Does Haemonetics (HAE) Have Enduring Growth Potential? Neutral

Mai 12, 2026 Haemonetics Q4 Earnings Call Highlights Bullish

Abr 21, 2026 Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation Neutral

Principais Movimentações

Ticker	Setor	Variação
HAE	Health Care	+20,9%

🤖 Visão geral AI

Ler mais

What happened: Haemonetics Corporation (HAE), a provider of blood management technologies, reported strong fiscal Q4 2025 results with revenue up 5% (9% organically) to $346 million and adjusted EPS of $1.29. For the full year, revenue reached $1.3 billion and adjusted EPS was $4.96. In Q1 2026, Haemonetics reported earnings of $33.01 million, or $0.72 per share, compared to $34.03 million, or $0.70 per share, last year. Riverwater Partners and Aristotle Capital Boston, LLC, both investment management companies, mentioned Haemonetics in their Q1 2026 investor letters, with Riverwater awaiting market validation for HAE.

Market impact: Haemonetics' robust performance has implications for the broader medical technology sector. The company's growth, driven by its Plasma and Blood Management Technologies, signals strength in the blood products market, which could benefit other players like Baxter International (BAX) and Terumo BCT. However, Riverwater's neutral stance suggests investors may be waiting for more market validation before fully committing to HAE's growth story.

What to watch next: Haemonetics' upcoming fiscal Q1 2026 earnings call on May 12, 2026, will provide further insight into the company's growth trajectory. Additionally, investors should keep an eye on the broader medical technology sector's performance, as any shifts in demand or regulatory changes could impact HAE's market validation narrative.

Visão Geral da IA em Ago 07, 2026

Cronologia

Primeira detecçãoAgo 09, 2026

Última atualizaçãoAgo 23, 2026

Haemonetics Corporation (HAE) aguarda validação do mercado

Principais Movimentações

Linha do Tempo de Sentimento

Desempenho por Setor

Linha do Tempo de Eventos

Artigos Relacionados